Sep 8, 2020
On August 23, 2020 the Food and Drug Administration’s announced a decision to grant blood plasma treatment for Coronavirus/Covid-19 patients with a fast-track authorization for its emergency use as a treatment for hospitalized COVID patients. This “emergency use authorization” triggered an outcry from scientists and doctors, who said the decision was not supported by adequate clinical evidence and criticized the FDA for what was perceived as bowing to political pressure. News coverage about this potential treatment has done little to clarify whether its useful or not. The idea that there could be a motivation behind the fast track authorization for this potential treatment other than looking for a useful therapeutic is troubling. More to the point, who should decide what patients receive in treatment for their illnesses? To help us make sense of how reforms for the pharmaceutical industry could potentially help separate facts from spin and who we should all listen to is respected neurologist, Dr. Steven Goldstein.